Clinical trial
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
NCT07903857 is registered in ClinicalTrials.gov with Guizhou Sinorda Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- Lead sponsor
- Guizhou Sinorda Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- February 28, 2030
- Enrollment
- 78 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal neoplasms, solid tumor malignancies, stomach neoplasms
Similar trials
Same condition (Stomach Neoplasms) and phase, most recent start first.
+434 more trials See the condition page